Prothena Corp Public (PRTA) Other Accumulated Expenses (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Other Accumulated Expenses of $10.5 million for Q1 2026, up 13.8% year-over-year from $9.2 million in Q1 2025, and down 10.92% quarter-over-quarter from $11.8 million in Q4 2025.
Analysis
Prothena Corp Public (PRTA) Other Accumulated Expenses (2012 - 2026) Analysis & Trends
Prothena Corp Public's Other Accumulated Expenses history runs 15 years deep, the most recent figure standing at $10.5 million for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 13.8% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (up 13.8% YoY), while the FY2025 annual figure was $11.8 million, down 25.61% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $10.5 million, down from $11.8 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $15.8 million in Q4 2024, with the low at $5.0 million in Q1 2022.
- The 5-year median for Other Accumulated Expenses is $10.5 million (2026), against an average of $10.7 million.
- The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses jumped 78.73% in 2022, then tumbled 42.61% in 2025.
- Prothena Corp Public's Other Accumulated Expenses stood at $12.2 million in 2022, then gained by 28.71% to $15.7 million in 2023, then increased by 1.16% to $15.8 million in 2024, then dropped by 25.61% to $11.8 million in 2025, then dropped by 10.92% to $10.5 million in 2026.
- Business Quant data shows PRTA's Other Accumulated Expenses at $10.5 million in Q1 2026, $11.8 million in Q4 2025, and $8.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Prothena Corp Public | 509.98 Mn | 221.78 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.24 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | 11.79 Mn |
| Sep 30, 2025 | 8.21 Mn |
| Jun 30, 2025 | 6.40 Mn |
| Mar 31, 2025 | 9.23 Mn |
| Dec 31, 2024 | 15.84 Mn |
| Sep 30, 2024 | 14.31 Mn |
| Jun 30, 2024 | 10.93 Mn |
| Mar 31, 2024 | 9.13 Mn |
| Dec 31, 2023 | 15.66 Mn |
| Sep 30, 2023 | 13.78 Mn |
| Jun 30, 2023 | 10.22 Mn |
| Mar 31, 2023 | 8.00 Mn |
| Dec 31, 2022 | 12.17 Mn |
| Sep 30, 2022 | 13.17 Mn |
| Jun 30, 2022 | 7.15 Mn |
| Mar 31, 2022 | 4.96 Mn |
| Dec 31, 2021 | 9.81 Mn |
| Sep 30, 2021 | 7.37 Mn |